Vivani Medical, Inc. (VANI) Form 8-K — Jun 30, 2026

$VANIForm 8-KItems 5.02, 5.07, 8.01, 9.01Filed Jun 30, 2026, 8:03 AM ET0001753926-26-001109Original filing

Vivani Medical announced regulatory approval from Bellberry in Australia to initiate SLIM-1, a Phase 1 clinical trial of NPM-139, a semaglutide implant. This approval marks a significant step forward in the development of the company's implantable drug delivery technology. In governance matters, stockholders approved an amendment and restatement of the 2022 Omnibus Incentive Plan, increasing the number of shares reserved for issuance by 11,000,000 to a total of 21,033,333 shares.

Key figures

Votes for proposal 1: 47572851
Votes for proposal 2: 47643763
Votes for proposal 3: 47128652
Votes for proposal 4: 61894328
Director nominees elected: 6
Total incentive plan shares: 21033333
Shares added to incentive plan: 11000000

Price after filing

1 day: -0.8%7 days: +8.9%30 days: +1.6%

Close on the filing date to close N calendar days later (from $1.24). Historical, not a forecast.

AI analysis

Red flags1 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.